Clinical Trial Update: Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients [Phase 4]

View source ↗

Summary

Phase 4 trial comparing modified-release dipyridamole/aspirin (200 mg/25 mg twice daily) versus aspirin alone (75 mg) in aspirin-resistant patients with coronar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Arteriosclerosis

Drugs mentioned

• Aspirin (Aspirin)
• Dipyridamole (Dipyridamole)
• Modified-release Dipyridamole/Aspirin

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Coronary Arteriosclerosis | Phase 4 | Status: COMPLETED